Selection of the best tumor antigen is critical for the therapeutic success of chimeric antigen receptor (CAR) T cells in hematologic malignancies and solid tumors. The anaplastic lymphoma kinase (ALK) receptor is ex-pressed by most neuroblastomas while virtually absent in most normal tissues. ALK is an oncogenic driver in neuroblastoma and ALK inhibitors show promising clinical activity. Here, we describe the development of ALK.CAR-T cells that show potent efficacy in monotherapy against neuroblastoma with high ALK expression without toxicity. For neuroblastoma with low ALK expression, combination with ALK inhibitors specifically potentiates ALK.CAR-T cells but not GD2.CAR-T cells. Mechanistically, ALK inhibitors impair tumor growth and upregulate the expression of ALK, thereby facilitating the activity of ALK.CAR-T cells against neuroblas-toma. Thus, while neither ALK inhibitors nor ALK.CAR-T cells will likely be sufficient as monotherapy in neu-roblastoma with low ALK density, their combination specifically enhances therapeutic efficacy.

ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells

Bergaggio, Elisa;Mota, Ines;Metovic, Jasna;Ambrogio, Chiara;Voena, Claudia;Papotti, Mauro;Chiarle, Roberto
2023-01-01

Abstract

Selection of the best tumor antigen is critical for the therapeutic success of chimeric antigen receptor (CAR) T cells in hematologic malignancies and solid tumors. The anaplastic lymphoma kinase (ALK) receptor is ex-pressed by most neuroblastomas while virtually absent in most normal tissues. ALK is an oncogenic driver in neuroblastoma and ALK inhibitors show promising clinical activity. Here, we describe the development of ALK.CAR-T cells that show potent efficacy in monotherapy against neuroblastoma with high ALK expression without toxicity. For neuroblastoma with low ALK expression, combination with ALK inhibitors specifically potentiates ALK.CAR-T cells but not GD2.CAR-T cells. Mechanistically, ALK inhibitors impair tumor growth and upregulate the expression of ALK, thereby facilitating the activity of ALK.CAR-T cells against neuroblas-toma. Thus, while neither ALK inhibitors nor ALK.CAR-T cells will likely be sufficient as monotherapy in neu-roblastoma with low ALK density, their combination specifically enhances therapeutic efficacy.
2023
41
12
2100
2116
ALK; adoptive T cell therapy; cell engineering; cellular immunity; chimeric antigen receptors; lorlatinib; neuroblastoma; solid tumors; tyrosine kinase inhibitors
Bergaggio, Elisa; Tai, Wei-Tien; Aroldi, Andrea; Mecca, Carmen; Landoni, Elisa; Nüesch, Manuel; Mota, Ines; Metovic, Jasna; Molinaro, Luca; Ma, Leyuan; Alvarado, Diego; Ambrogio, Chiara; Voena, Claudia; Blasco, Rafael B; Li, Tongqing; Klein, Daryl; Irvine, Darrell J; Papotti, Mauro; Savoldo, Barbara; Dotti, Gianpietro; Chiarle, Roberto
File in questo prodotto:
File Dimensione Formato  
Bergaggio et al Cancer Cell 2023.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 29.94 MB
Formato Adobe PDF
29.94 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1956156
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 0
social impact